HHS Opened Pharmacy Access to BPC-157. Its Only Colitis Trial Had 53 Patients.

Picture a small glass vial with a handwritten-looking label, the kind that turns up in gym bags, wellness-clinic menus and videos promising to fix a leaky gut. That vial is BPC-157, and as of this week a pharmacy can mix it for you without federal enforcement standing in the way. We read the government’s notice, then went back to the review FDA scientists wrote about this exact peptide in July, the one that asked the question its fans care about most: does it heal the gut? The answer FDA wrote down is short. One small trial, two weeks long, never published in full.

Here is what changed, what the gut evidence is, and what the second peptide on the list, KPV, rests on.

The policy: HHS will not stop pharmacies from compounding BPC-157 while FDA decides

The Department of Health and Human Services filed a notice with the Federal Register on Wednesday, October 28, 2026, announcing an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” In plain terms, HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A,” according to the notice, FR Doc. 2026-22192, scheduled for publication on October 30.

The same HHS notice says what the policy is not. “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed,” it reads, and HHS may revisit the policy if “a safety signal or product quality issue arises.” Comments are open for two weeks after publication on docket HHS-OASH-2026-0496. The six peptides covered are BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, the six that an FDA advisory committee recommended in July. As reported by the FDA Law Blog of the firm Hyman, Phelps & McNamara on October 28, the policy allows BPC-157 acetate in injected, oral and topical forms and KPV acetate in topical and oral forms. We could not open the HHS appendix itself from our location, so those route details are theirs.

The gut claim: BPC-157 was nominated for colitis, Crohn’s and celiac disease

BPC-157 is a 15-amino-acid peptide described as a fragment of a protein “found in gastric juice,” and it was “first described in 1993,” according to the FDA briefing document on BPC-157 prepared for the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026. The stomach origin is the root of its gut reputation. The pharmacies that nominated it proposed it for “UC, Crohn’s disease, Celiac disease, and tendonitis,” the briefing says. FDA evaluated only ulcerative colitis, the inflammatory bowel disease that affects the lining of the colon, because the nomination did not include enough information on the other uses.

The demand is not hypothetical. The same FDA briefing quotes clinic and pharmacy websites claiming BPC-157 can “decrease inflammation of the stomach and intestines, which can improve irritable bowel syndrome, stomach ulcers, chron’s [sic] disease, and ulcerative colitis,” and cites a 2025 paper counting “over 50 million ‘BPC-157’ tagged video views on both YouTube and TikTok.” On October 28, Google’s autocomplete finished “bpc 157 gut” with healing, repair and inflammation.

The evidence: One trial, 53 patients, two weeks, and an answer the trial could not give

FDA reviewers found a single trial of BPC-157 in ulcerative colitis: a multicenter, placebo-controlled study reported only as a 2005 meeting abstract, in which 53 people with mild to moderate disease received a BPC-157 enema of 80 mg or a placebo once a day for two weeks, according to the FDA briefing. Forty-six finished. The disease activity score fell 3.2 points on BPC-157 and 1.6 points on placebo, and the estimated difference between the groups came with a 95% confidence interval running from −4.84 to 1.62.

Our reading: an interval that runs through zero means the trial could not tell BPC-157 apart from the placebo enema. FDA’s own words were that the data “are therefore inadequate to support the efficacy and safety of BPC-157 given as an enema for two weeks for the treatment of UC.” The reviewers also wrote that they “did not identify any studies that administered BPC-157 via the oral, SC, nasal, or transdermal” route in people with colitis. The capsules and injections people actually buy have never been tested in colitis.

Across every use, FDA’s search turned up five clinical studies of BPC-157: enemas in 24 healthy volunteers for up to eight days, enemas in about 26 colitis patients for two weeks, knee injections in 17 people, a bladder instillation in 12 and an intravenous infusion in two. By our arithmetic that is about 81 people who received the peptide, none for longer than two weeks. “No serious adverse events appear to have been reported,” the briefing says, but the studies were short and small, and the most frequent side effects of the enema in healthy volunteers were “headache and flatulence.” An October 2026 systematic review in Acta Orthopaedica Belgica (PMID 42885452) counted three human studies with 30 participants and rated the certainty of the evidence “very low”; the intravenous study it included, PMID 40131143, had two participants.

The mechanism: What happens to a peptide in the gut, and what FDA could not answer

Peptides are short chains of amino acids, and the gut is built to break chains like that down. FDA reviewers noted that BPC-157 was reported to resist digestion in gastric juice in a lab dish, but that “there is no information to assess the pharmacokinetics of BPC-157 in humans,” meaning nobody has measured what happens to an oral dose. In the enema studies, the peptide was not detected in blood, and the briefing concludes “it does not appear that BPC-157 is absorbed systemically when given as a rectal enema.” Rat studies report protection against gut lesions, but FDA wrote that the peptide’s “molecular targets” have not been identified.

The reviewers’ larger concern was the peptide itself. They wrote that BPC-157 is not well characterized chemically and that, injected or sprayed into the nose, a 15-amino-acid peptide “may pose a significant risk for immunogenicity,” an unwanted immune response, made worse by clumping or impurities. Their recommendation was to keep it off the list, partly because “there are FDA-approved drug products that are indicated to treat UC, a serious chronic disease that may cause life-threatening complications.”

The second gut peptide: KPV is sold for colitis and Crohn’s, and FDA found no human studies

KPV is a three-amino-acid fragment of alpha-MSH, a hormone made in the pituitary gland, according to FDA’s KPV briefing document. Its nominator proposed it for wound healing and skin inflammation such as psoriasis and eczema, but the briefing notes that online it “is also promoted for inflammatory bowel diseases, colitis, and Crohn’s disease.” The evidence for that comes from animals: a 2008 Gastroenterology study (PMID 18061177) found that KPV in drinking water reduced inflammation in two mouse models of colitis. In people, FDA reviewers “did not identify data, such as clinical studies, on the use of KPV in humans,” and proposed keeping it off the list as well.

The advisory committee disagreed with the staff on both. At the July 23 session, where it voted on BPC-157 and KPV, the committee voted 8 to 6 with one abstention to recommend them, as reported by RAPS. Advisory votes are not binding; this week’s HHS policy is what turned them into access.

The everyday version: What this means if your gut is the reason you were looking

The policy changes who can legally make BPC-157 and KPV. It does not change what is known about them. For ulcerative colitis, Crohn’s disease and celiac disease, the conditions BPC-157 was nominated for, there are approved treatments and, for celiac disease, a gluten-free diet with decades of evidence behind it. Anyone weighing a peptide for a gut condition can bring the public FDA briefing to a gastroenterologist; it lays out exactly what has and has not been tested.

How we checked this: Sources and method

We read the HHS notice, Federal Register document 2026-22192 (filed October 28, 2026), and FDA’s July 2026 briefing documents for BPC-157 and KPV at source. The HHS appendix returned an access error to us, so the routes are as reported by the FDA Law Blog on October 28; the 8 to 6 vote is as reported by RAPS on July 23. Papers are cited by PubMed ID, each matched to its title: 42885452 (systematic review, 2026), 40131143 (intravenous pilot, 2025) and 18061177 (KPV in mouse colitis, 2008). The 2005 colitis trial was available only as a meeting abstract summarized by FDA. Search completions were read from Google autocomplete on October 28. The total of 81 participants and the reading of the confidence interval are our arithmetic and our reading. This article is educational, describes what the cited sources say, and is not medical advice.